Cellestia plans Phase II for solid, blood cancers with $20M series B

Cellestia is developing what could be a first-in-class small molecule that prevents assembly of transcription factor complexes that activate oncogene expression, and has raised CHF20 million ($20.3 million) in a B round that’ll enable completion of Phase II testing of the compound.

Series A investor FC Capital led the B round with participation from seed and A round VC PPF Group, as well as Partners Investment and additional undisclosed investors...